JP2018502087A - Ｒａｆ阻害剤及びタキサンの組み合わせ - Google Patents

Ｒａｆ阻害剤及びタキサンの組み合わせ Download PDF

Info

Publication number
JP2018502087A
JP2018502087A JP2017533810A JP2017533810A JP2018502087A JP 2018502087 A JP2018502087 A JP 2018502087A JP 2017533810 A JP2017533810 A JP 2017533810A JP 2017533810 A JP2017533810 A JP 2017533810A JP 2018502087 A JP2018502087 A JP 2018502087A
Authority
JP
Japan
Prior art keywords
cancer
raf
pharmaceutically acceptable
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017533810A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502087A5 (enExample
Inventor
ヴィヴィアーナ ボゾン，
ヴィヴィアーナ ボゾン，
キャサリン エム． ガルビン，
キャサリン エム． ガルビン，
レイチェル エル． ブレイク，
レイチェル エル． ブレイク，
チュンリ シュー，
チュンリ シュー，
カルッピア カナン，
カルッピア カナン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2018502087A publication Critical patent/JP2018502087A/ja
Publication of JP2018502087A5 publication Critical patent/JP2018502087A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017533810A 2014-12-23 2015-12-22 Ｒａｆ阻害剤及びタキサンの組み合わせ Pending JP2018502087A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462096020P 2014-12-23 2014-12-23
US62/096,020 2014-12-23
US201562242629P 2015-10-16 2015-10-16
US62/242,629 2015-10-16
PCT/US2015/067462 WO2016106359A1 (en) 2014-12-23 2015-12-22 Combination of raf inhibitors and taxanes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020065763A Division JP2020114857A (ja) 2014-12-23 2020-04-01 Ｒａｆ阻害剤及びタキサンの組み合わせ

Publications (2)

Publication Number Publication Date
JP2018502087A true JP2018502087A (ja) 2018-01-25
JP2018502087A5 JP2018502087A5 (enExample) 2019-02-07

Family

ID=56151531

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017533810A Pending JP2018502087A (ja) 2014-12-23 2015-12-22 Ｒａｆ阻害剤及びタキサンの組み合わせ
JP2020065763A Pending JP2020114857A (ja) 2014-12-23 2020-04-01 Ｒａｆ阻害剤及びタキサンの組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020065763A Pending JP2020114857A (ja) 2014-12-23 2020-04-01 Ｒａｆ阻害剤及びタキサンの組み合わせ

Country Status (7)

Country Link
US (2) US20190117652A1 (enExample)
EP (1) EP3236966B1 (enExample)
JP (2) JP2018502087A (enExample)
CN (1) CN107405348B (enExample)
CA (1) CA2972189A1 (enExample)
ES (1) ES2827024T3 (enExample)
WO (1) WO2016106359A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4065122A4 (en) * 2019-11-27 2023-12-27 Day One Biopharmaceuticals, Inc. Solid dispersion of pan-raf kinase inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010532380A (ja) * 2007-06-29 2010-10-07 サネシス ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用な化合物
WO2013144923A1 (en) * 2012-03-30 2013-10-03 Takeda Pharmaceutical Company Limited Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma
WO2014138279A1 (en) * 2013-03-05 2014-09-12 University Of Tennessee Research Foundation Compounds for treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2694646C (en) * 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
JO3101B1 (ar) * 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
KR20110100241A (ko) * 2008-12-05 2011-09-09 아르퀼 인코포레이티드 Ｒａｆ 억제제 및 이들의 용도
RU2553379C2 (ru) * 2009-08-24 2015-06-10 Дженентек, Инк. ОПРЕДЕЛЕНИЕ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК К ОБРАБОТКЕ ИНГИБИТОРОМ B-Raf ПУТЕМ ДЕТЕКЦИИ МУТАЦИИ K-ras И УРОВНЕЙ ЭКСПРЕССИИ RTK
UY36046A (es) * 2014-03-26 2015-10-30 Millennium Pharm Inc Formulaciones farmacéuticas, procesos para la preparación y métodos de uso

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010532380A (ja) * 2007-06-29 2010-10-07 サネシス ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用な化合物
WO2013144923A1 (en) * 2012-03-30 2013-10-03 Takeda Pharmaceutical Company Limited Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma
WO2014138279A1 (en) * 2013-03-05 2014-09-12 University Of Tennessee Research Foundation Compounds for treatment of cancer

Also Published As

Publication number Publication date
CA2972189A1 (en) 2016-06-30
ES2827024T3 (es) 2021-05-19
JP2020114857A (ja) 2020-07-30
EP3236966A4 (en) 2018-10-03
EP3236966B1 (en) 2020-08-12
US20200316067A1 (en) 2020-10-08
WO2016106359A1 (en) 2016-06-30
EP3236966A1 (en) 2017-11-01
CN107405348A (zh) 2017-11-28
US20190117652A1 (en) 2019-04-25
CN107405348B (zh) 2021-06-11

Similar Documents

Publication Publication Date Title
Assi et al. Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia
IL300450A (en) Bicyclic conjugates specific to nectin-4 and uses thereof
US20240254120A1 (en) Ep4 inhibitors and synthesis thereof
US20130231347A1 (en) Method of treatment with braf inhibitor
JP6571105B2 (ja) 汎ｒａｆキナーゼ阻害剤の薬学的製剤、その調製プロセス、及び使用方法
JP2024081710A (ja) ウイルス感染、炎症又は癌の処置におけるバイオマーカー及び使用
US20180263979A1 (en) Combination of raf inhibitors and aurora kinase inhibitors
US20200063214A1 (en) Methods of identifying patients likely to benefit from treatment with a telomerase inhibitor
WO2023114984A1 (en) Tead inhibitors and uses thereof
WO2020150480A1 (en) Methods for treatment of lung cancers
RS67265B1 (sr) Lečenje kancera koji ima gnaq ili gna11 genetske mutacije sa inhibitorima protein kinaze c
US20200316067A1 (en) Combination of raf inhibitors and taxanes
WO2017066664A1 (en) Combination therapy including a raf inhibitor for the treatment of colorectal cancer
Ohno Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
US8697681B2 (en) Method for prediction of therapeutic effect of chemotherapy employing expression level of dihydropyrimidine dehydrogenase gene as measure
WO2025217209A2 (en) Crystalline forms of hdac inhibitor and uses thereof
WO2016106351A1 (en) Combination of raf inhibitors and mtor inhibitors
WO2013147750A1 (en) Oral combination therapy for treating hcv infection in specific patient sub-population
Jabbour et al. and Hagop Kantarjian, MD

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200401

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200527

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200817